Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92833
UPID:
JARD2_HUMAN
Alternative names:
Jumonji/ARID domain-containing protein 2
Alternative UPACC:
Q92833; A8K9Z6; B7Z5S5; B7Z8L0; Q5U5L5; Q86X63
Background:
Protein Jumonji, also known as Jumonji/ARID domain-containing protein 2, is a pivotal regulator in embryonic development, influencing heart and liver formation, neural tube fusion, and hematopoiesis. It functions as an accessory unit for the PRC2 complex, facilitating histone H3K27 trimethylation, essential for DNA binding and stem cell differentiation.
Therapeutic significance:
Linked to developmental delay with variable intellectual disability and dysmorphic facies, understanding the role of Protein Jumonji could open doors to potential therapeutic strategies.